When do rising drug prices not equal rising sales? When payers step in to control costs--and that's exactly what they've been doing.
Advertising experts have a few tricks up their sleeves when concocting a drug's proprietary name--like Zytiga, Xtandi and Xeljanz--that might thrust the product to success. Now, the FDA is looking for ideas about allowing drugmakers to reserve these names in advance--with a few rules.
Drugmakers cheer when influential doctors' groups revise treatment guidelines to include new drugs. But as AstraZeneca's MedImmune unit knows, those groups can backpedal.
The job-cutting ax has come out for Merck's U.S. field force, as part of a move to cut 600 positions by August.
The chilly sales climate in China is just now warming up after last summer's wave of bribery accusations spooked doctors and sales reps. But as far as Merck KGaA is concerned, China is warm enough to deliver doubled revenues in the region. And that's exactly what the German drugmaker's shooting for.
It is fascinating what has happened in the last couple of years in the animal health industry, which runs to $22 billion a year for animal drugs and vaccines and is expected to grow at 5.7% compound...
A Bloomber g editor takes to the halls of dog food producer Blue Buffalo in Wilton, CT, to find out if the company is "built on lies," as alleged by the company's archnemesis, Purina.
Armed with a brand-new FDA approval for its blood cancer drug Zydelig (idelalisib), Gilead will take on the oncology market.
If someone asked who you'd turn to for relationship advice, chances are you wouldn't say Pfizer. But that could change.
A time-honored technique for boosting drug sales is simple: Raise prices. Lately, plenty of drugmakers pressed by patent-cliff losses have done just that. But some notable price hikes on diabetes drugs may be backfiring with payers. With diabetes costs taking double-digit increases--and expensive newer meds launching--insurers are tightening restrictions on drug use.